SCHEMBL3482615

SCHEMBL3482615

Cc1ccc([Si](C)(C)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.47
TDP1 Q9NUW8 1/20 0.47
NR1I2 O75469 3/20 0.38
ALDH1A1 P00352 6/20 0.38
LMNA P02545 3/20 0.38
CA2 P00918 2/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
LPL P06858 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
ORAI1 Q96D31 1/20 0.38
ORAI2 Q96SN7 1/20 0.38
ORAI3 Q9BRQ5 1/20 0.38
TRPV6 Q9H1D0 1/20 0.38
CA1 P00915 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TSHR P16473 3/20 0.35
NOTUM Q6P988 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL235602 0.87 NR1I2 (0.43) NR1I2HPGD
SCHEMBL7902561 0.84 NR1I2 (0.42) NR1I2HPGD
SCHEMBL15445504 0.82 ACHE (0.47) ACHETDP1ALDH1A1LMNACA2
SCHEMBL1054613 0.81 ACHE (0.53) ACHETDP1ALDH1A1LMNACA2
SCHEMBL11979357 0.79 NR1H2 (0.46) ACHENR1I2HPGDGAA
SCHEMBL1686889 0.79 ACHE (0.50) ACHETDP1ALDH1A1LMNACA2
SCHEMBL29086820 0.79 NR1I2 (0.39) NR1I2HPGD
SCHEMBL7862066 0.79 ACHE (0.50) ACHETDP1ALDH1A1LMNACA2
SCHEMBL29242328 0.79 ESR1 (0.50) NR1I2HPGD
SCHEMBL1686464 0.79 ACHE (0.50) ACHETDP1ALDH1A1LMNACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203077-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME NATIONAL SCIENCE FOUNDATION 2023-06-29 US disclosed
US-20230102728-A1 METHOD OF PREPARING SILANOLS WITH SELECTIVE CYTOCHROME P450 VARIANTS AND RELATED COMPOUNDS AND COMPOSITIONS CALIFORNIA INSTITUTE OF TECHNOLOGY 2023-03-30 US disclosed
US-10723845-B2 Process for preparing linear carbosiloxane polymers DOW SILICONES CORPORATION (US) 2020-07-28 US disclosed
US-20200079911-A1 PROCESS FOR PREPARING LINEAR CARBOSILOXANE POLYMERS DOW CORNING EUROPE S.A. 2020-03-12 US disclosed
EP-3153540-B1 PROCESS FOR PREPARING LINEAR CARBOSILOXANE POLYMERS DOW CORNING (US) 2018-06-06 EP disclosed
US-20170305948-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME UNIV YALE (US) 2017-10-26 US disclosed
WO-2017062091-A1 PROCESS FOR PREPARING LINEAR CARBOSILOXANE POLYMERS DOW CORNING CORPORATION (US) 2017-04-13 WO disclosed
EP-3153540-A1 PROCESS FOR PREPARING LINEAR CARBOSILOXANE POLYMERS Dow Corning Corporation (US) 2017-04-12 EP disclosed
EP-2128897-B1 SILICON DIELECTRIC TREATING AGENT FOR USE AFTER ETCHING, PROCESS FOR PRODUCING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJITSU LTD (JP) 2015-05-06 EP disclosed
US-8716209-B2 Agent for post-etch treatment of silicon dielectric film, method of manufacturing semiconductor device, and semiconductor device FUJITSU LIMITED (JP) 2014-05-06 US disclosed
US-20090192265-A1 Curable composition KANEKA CORPORATION (JP) 2009-07-30 US disclosed
US-7511102-B2 Polymer and liquid gasket for In-Place forming KANEKA CORPORATION (JP) 2009-03-31 US disclosed
US-20080177001-A1 CURABLE COMPOSITIONS KANEKA CORPORATION (JP) 2008-07-24 US disclosed
US-7388038-B2 Curable compositions KANEKA CORPORATION (JP) 2008-06-17 US disclosed
US-20070276066-A1 Curing Composition KANEKA CORPORATION (JP) 2007-11-29 US disclosed
US-20070225436-A1 Curable Composition KANEKA CORPORATION (JP) 2007-09-27 US disclosed
US-20070213459-A1 Curable Composition KANEKA CORPORATION (JP) 2007-09-13 US disclosed
US-20070167583-A1 Curable composition KANEKA CORPORATION (JP) 2007-07-19 US disclosed
US-20070161732-A1 Novel polymer and liquid gasket for In-Place forming KANEKA CORPORATION (JP) 2007-07-12 US disclosed
US-7186780-B2 Polymer and liquid gasket for in-place forming KANEKA CORPORATION (JP) 2007-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230102728-A1 METHOD OF PREPARING SILANOLS WITH SELECTIVE CYTOCHROME P450 VARIANTS AND RELATED COMPOUNDS AND COMPOSITIONS CYP2E1, POR, CYP3A43 ACHE 2878/4885TDP1 2684/4885NR1I2 511/4885
US-20230203077-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME TIMCC, YAP1, TET2 ACHE 814/4885TDP1 2408/4885NR1I2 4809/4885
US-20170305948-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME TIMCC, YAP1, TET2 ACHE 814/4885TDP1 2408/4885NR1I2 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.